clinical studies

World Multiple Sclerosis Day, as a day of global solidarity, emphasizes the need to raise awareness of this disease, improve diagnosis and treatment, and fund research to curb multiple sclerosis.

At mediri we develop and refine structural analysis methods to support the diagnosis and follow-up of multiple sclerosis.
An important imaging biomarker for MS is smouldering lesions. Their AI-aided detection on MR images also makes disease activity visible that cannot be seen with the naked eye.

30 years after the first successful Arterial Spin Labeling (ASL) MR image acquisition to measure cerebral blood flow in rat brain, the early detection of Alzheimer’s using ASL gains enormous importance with the recent publication of the study results for Lecanemab. Now that there is hope for efficient therapies in dementia diseases, it is a good time to review the steps that have been gone since then. Many initiatives aiming at reliable and comparable quantification of brain perfusion measurements are paving the way for broad usage of ASL in clinical studies focusing on Alzheimer‘s and other dementia diseases.

We are looking forward to the installation of our WHITEBOX at the Universitätsmedizin Mannheim. It will allow for fast and pseudonymized DICOM image transfer from CT scanner to mTRIAL study server. The results of AI based image analysis will be sent directly to the radiologist on duty.

Also looking for easy DICOM upload options? Contact us via info@mediri.com.

In honor of todays International Day of Radiology, we want to thank again the attendees of the 8th International Symposium on Focused Ultrasound (23.10.2022 – 27.10.2022) for valuating the contribution of our colleague Jürgen Jenne. The topic covered the first steps towards an automated and generalized definition of target and areas of risk in tcMRgFUS (transcranial therapy with MR-guided focused ultrasound) for tremor therapy. One part of the presented work was to establish a robust method for fiber tracking on brain MR images.

Our new mTRIAL release will come with a full featured browser based DICOM viewer on board. Designed for clinical trial data management, it supports segmentation, annotation and scoring tasks as defined in the study protocol. The OHIF based tool can be adapted to your personal needs and study requirements.

Curious? Contact us for a free demo via info@mediri.com.

We are excited to announce that mediri is working together with the Universitätsmedizin Mannheim on the project “DeepRAY“. The goal of the project is to extend mediri’s mTRIAL platform for AI-based detection of aneurysms and dissections of the aorta on CT images. This will improve the prognosis of patients with life-threatening changes in the abdominal aorta. The investBW project will run for two years and is funded by the Ministerium für Wirtschaft, Arbeit und Tourismus Baden-Württemberg.

We are delighted to share that we have a new Chief Operations Officer: Julia Müller will from now on take care of mediri’s fortune. She takes over from Prof. Johannes Gregori who will be remaining on board as mediri’s Director of Research.

We are proud to announce that our quality management system was re-certified according to EN ISO 13485. Our Software development processes fulfill the requirements for medical devices.

It’s great to be in-person again. After a meeting on the advances in the ASPIRE project together with GSP and VUmc, mediri enjoyed extensive scientific exchange and insights to latest developments in MRI at ISMRM in London. Also thanks to everyone for joining the ASL Network Dinner during ISMRM 2022.